Results 71 to 80 of about 7,735 (172)
Fruquintinib: Mechanism of Action, Clinical, and Translational Science
Clinical and Translational Science, Volume 19, Issue 10, October 2026.ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou +7 more
wiley +1 more source
Dabigatran etexilate and COVID-19
, 2021 Thrombotic complications are frequent in COVID-19. There is evidence supporting the use of prophylactic dose low molecular weight heparin (LMWH) as prophylaxis for venous thromboembolism in critically ill patients. Indeed, all patients with COVID-19 that
Domina Petric
core +1 more source
Therapeutic Advances in Neurological Disorders, 2014 Background: There are growing concerns for the side effects of dabigatran etexilate (dabigatran), including higher incidence of dyspepsia and gastrointestinal bleeding.
Georgios Tsivgoulis +15 more
doaj +1 more source
PLoS ONE, 2012 BackgroundDabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost ...
Joyce H S You +3 more
doaj +1 more source
International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 1181-1188, October 2026.ABSTRACT Introduction Lupus anticoagulant (LA) testing is essential, albeit complex, in the laboratory diagnosis of antiphospholipid syndrome (APS). Given the multi‐step workflow and the variability introduced by anticoagulant therapy, reagent differences, and interpretive approaches, result interpretation requires expert evaluation.
Chiara Novelli +4 more
wiley +1 more source
Drug-Induced Exanthem Following Dabigatran
, 2011 Objective: To report an incident of a drug-induced exanthem during treatment with dabigatran in a patient without prior exposure to the drug. Case Summary: A 20-year-old white male was prescribed oral dabigatran 150 mg twice daily for thromboembolic ...
John Hummel +3 more
core +1 more source
Dabigatran experience in primary and secondary prevention of cardioembolic stroke
Неврология, нейропсихиатрия, психосоматика, 2013 The review of novel oral anticoagulants (dabigatran, rivaroxaban and apixaban) in stroke prevention and also own data of administration of dabigatran in primary and secondary prevention of ischemic stroke in 45 patients with cerebrovascular diseases are ...
Maksim Alekseyevich Domashenko +3 more
doaj +1 more source
Dabigatran Use Associated with Hemopericardium and Hemothorax [PDF]
, 2020 Concurrent spontaneous hemopericardium and hemothorax due to anticoagulant use are extremely rare in clinical practice. Dabigatran is an oral direct thrombin inhibitor approved to prevent stroke or thromboembolic episodes in patients with nonvalvular ...
Josip Katić +13 more
core +1 more source
Dabigatran and laboratory tests [Dabigatran e analisi di laboratorio]
, 2015 New oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban) are now available. In using these drugs, routine monitoring of laboratory coagulation tests is not recommended.
Molon, G +6 more
core +1 more source
Healthcare utilization and costs for patients initiating Dabigatran or Warfarin
Health and Quality of Life Outcomes, 2017 Background Novel oral anticoagulants (NOAC) such as dabigatran, when compared to warfarin, have been shown to potentially reduce the risk of stroke in patients with non-valvular atrial fibrillation (NVAF) together with lower healthcare resource ...
Shannon L. Reynolds +9 more
doaj +1 more source